ALK-Positive Non-Small Cell Lung Cancer Initial and continuing PBS authority application Supporting information form (PB156)

You must lodge this form for a patient starting initial or continuing Pharmaceutical Benefits Scheme (PBS) subsidised treatment with crizotinib for Stage IIIB (locally advanced) or Stage IV (metastatic) ALK-Positive non squamous type Non-Small Cell Lung Cancer (NSCLC) or not otherwise specified NSCLC.

 

Page last updated: 5 February 2016

This information was printed Friday 30 September 2016 from humanservices.gov.au/health-professionals/forms/pb156 It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.